ONKURE THERAPEUTICS INC-A (OKUR) Fundamental Analysis & Valuation

NASDAQ:OKUR • US68277Q1058

Current stock price

3.79 USD
-0.2 (-5.01%)
At close:
3.79 USD
0 (0%)
Pre-Market:

This OKUR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. OKUR Profitability Analysis

1.1 Basic Checks

  • In the past year OKUR has reported negative net income.
  • In the past year OKUR has reported a negative cash flow from operations.
  • In the past 5 years OKUR always reported negative net income.
  • In the past 5 years OKUR always reported negative operating cash flow.
OKUR Yearly Net Income VS EBIT VS OCF VS FCFOKUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • OKUR has a Return On Assets of -95.81%. This is in the lower half of the industry: OKUR underperforms 74.47% of its industry peers.
  • Looking at the Return On Equity, with a value of -105.93%, OKUR is in line with its industry, outperforming 42.94% of the companies in the same industry.
Industry RankSector Rank
ROA -95.81%
ROE -105.93%
ROIC N/A
ROA(3y)-71.23%
ROA(5y)-57.51%
ROE(3y)-81.33%
ROE(5y)-64.6%
ROIC(3y)N/A
ROIC(5y)N/A
OKUR Yearly ROA, ROE, ROICOKUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • OKUR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OKUR Yearly Profit, Operating, Gross MarginsOKUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. OKUR Health Analysis

2.1 Basic Checks

  • OKUR has more shares outstanding than it did 1 year ago.
  • OKUR has less shares outstanding than it did 5 years ago.
  • OKUR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OKUR Yearly Shares OutstandingOKUR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
OKUR Yearly Total Debt VS Total AssetsOKUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -1.87, we must say that OKUR is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of OKUR (-1.87) is comparable to the rest of the industry.
  • OKUR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.87
ROIC/WACCN/A
WACCN/A
OKUR Yearly LT Debt VS Equity VS FCFOKUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 10.28 indicates that OKUR has no problem at all paying its short term obligations.
  • OKUR's Current ratio of 10.28 is amongst the best of the industry. OKUR outperforms 80.85% of its industry peers.
  • OKUR has a Quick Ratio of 10.28. This indicates that OKUR is financially healthy and has no problem in meeting its short term obligations.
  • OKUR has a Quick ratio of 10.28. This is amongst the best in the industry. OKUR outperforms 80.85% of its industry peers.
Industry RankSector Rank
Current Ratio 10.28
Quick Ratio 10.28
OKUR Yearly Current Assets VS Current LiabilitesOKUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. OKUR Growth Analysis

3.1 Past

  • OKUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.88%, which is quite impressive.
EPS 1Y (TTM)32.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 13.74% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.84%
EPS Next 2Y12.93%
EPS Next 3Y13.74%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OKUR Yearly Revenue VS EstimatesOKUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 200K 400K 600K 800K 1M
OKUR Yearly EPS VS EstimatesOKUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. OKUR Valuation Analysis

4.1 Price/Earnings Ratio

  • OKUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OKUR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OKUR Price Earnings VS Forward Price EarningsOKUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OKUR Per share dataOKUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as OKUR's earnings are expected to grow with 13.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.93%
EPS Next 3Y13.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OKUR Dividend Analysis

5.1 Amount

  • OKUR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OKUR Fundamentals: All Metrics, Ratios and Statistics

ONKURE THERAPEUTICS INC-A

NASDAQ:OKUR (3/30/2026, 8:23:12 PM)

Premarket: 3.79 0 (0%)

3.79

-0.2 (-5.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-04
Inst Owners85.09%
Inst Owner Change13.2%
Ins Owners1.7%
Ins Owner Change0.6%
Market Cap51.81M
Revenue(TTM)N/A
Net Income(TTM)-59.52M
Analysts85
Price Target25.3 (567.55%)
Short Float %0.06%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.27%
Min EPS beat(2)10.8%
Max EPS beat(2)15.75%
EPS beat(4)4
Avg EPS beat(4)14.27%
Min EPS beat(4)10.44%
Max EPS beat(4)20.09%
EPS beat(8)5
Avg EPS beat(8)-5.26%
EPS beat(12)7
Avg EPS beat(12)-6.76%
EPS beat(16)11
Avg EPS beat(16)-2.7%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.75%
PT rev (3m)-2.75%
EPS NQ rev (1m)25.65%
EPS NQ rev (3m)25.65%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-4.41
EYN/A
EPS(NY)-3.8
Fwd EYN/A
FCF(TTM)-3.79
FCFYN/A
OCF(TTM)-3.79
OCFYN/A
SpS0
BVpS4.11
TBVpS4.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -95.81%
ROE -105.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.23%
ROA(5y)-57.51%
ROE(3y)-81.33%
ROE(5y)-64.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.29%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.28
Quick Ratio 10.28
Altman-Z -1.87
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)50.54%
Cap/Depr(5y)188.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
EPS Next Y13.84%
EPS Next 2Y12.93%
EPS Next 3Y13.74%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.39%
OCF growth 3YN/A
OCF growth 5YN/A

ONKURE THERAPEUTICS INC-A / OKUR Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ONKURE THERAPEUTICS INC-A?

ChartMill assigns a fundamental rating of 2 / 10 to OKUR.


What is the valuation status for OKUR stock?

ChartMill assigns a valuation rating of 0 / 10 to ONKURE THERAPEUTICS INC-A (OKUR). This can be considered as Overvalued.


Can you provide the profitability details for ONKURE THERAPEUTICS INC-A?

ONKURE THERAPEUTICS INC-A (OKUR) has a profitability rating of 0 / 10.


What is the financial health of ONKURE THERAPEUTICS INC-A (OKUR) stock?

The financial health rating of ONKURE THERAPEUTICS INC-A (OKUR) is 7 / 10.